After a five-decade drought, lupus patients have a new first-line treatment against the autoimmune disease: Human Genome Sciences' ($HGSI) Benlysta. The drug has blockbuster potential for the company, and its partner, GlaxoSmithKline ($GSK). Following the treatment's landmark approval, we're looking back at the ups and downs of Benlysta's R&D journey. See the timeline >>